Loading organizations...
§ Private Profile · Palo Alto, CA, USA
An immune-oncology company developing therapies for cancer immune evasion pathways, focused on blocking the CD47 protein.
Forty Seven is a Stanford, California-based immuno-oncology company that develops specialized therapeutic treatments targeting cancer immune evasion pathways by specifically blocking the CD47 protein. The biotechnology firm officially launched its independent operations with a $75 million Series A financing round in February 2016 before successfully completing its initial public offering in 2018. In March 2020, multinational pharmaceutical giant Gilead Sciences acquired the enterprise for approximately $4.9 billion to integrate its clinical pipeline and expand its broader cancer immunotherapy portfolio. Prior to the corporate acquisition, the organization focused its primary research and development efforts on its lead therapeutic candidate, magrolimab, which was designed to enhance anti-tumor efficacy by preventing cancer cells from evading the human immune system. The underlying biotechnology enterprise was originally founded in 2015 by Stanford University researchers Irv Weissman and Ravindra Majeti.
Forty Seven has raised $160.2M across 3 funding rounds.
Forty Seven has raised $160.2M in total across 3 funding rounds.
Forty Seven (fortyseven.ai) is a technology consultancy specializing in AI strategy, machine learning, and custom AI solutions for high-growth companies. It partners with clients to implement purposeful AI designs that deliver immediate impact, high-impact execution, and long-term results, transforming market players into disruptors through tailored services like prototyping, executive training, and bespoke software development.[1][2]
The company serves high-growth businesses across sectors adopting AI, such as cybersecurity, CRM, and content production, solving challenges in AI readiness, strategic planning, and integration to boost productivity and competitive edges. Its growth momentum aligns with surging AI adoption among S&P 500 firms and Nvidia's hardware advances, offering 3-6 month engagements for rapid value creation.[1][2]
Forty Seven was co-founded by Steve McKean (CEO) and Daniel Rodriguez (CTO), both with over 20 years in technology startups as founders, investors, and board members. McKean founded and chaired ApexEdge while serving as a Certified Vjal AI trainer; Rodriguez founded Scattered Metal and holds patents in AI, blockchain, and robotics.[1][2]
The idea emerged from their deep expertise to address the pivotal moment in AI adoption, focusing on blending technology with human experience—symbolized by the number 47 for balance and harmony. Early traction built on hands-on workshops and training, evolving into a systematic approach of AI readiness assessments, roadmaps, and implementations for high-growth clients.[1][2]
Forty Seven rides the AI adoption wave, capitalizing on a pivotal era where S&P 500 companies integrate AI into core operations amid Nvidia's GPU breakthroughs enabling advanced applications in cybersecurity, CRM, and content. This timing matters as businesses race for competitive edges, with market forces like talent shortages and rising costs favoring consultancies offering immediate, scalable AI transformations.[2]
It influences the ecosystem by empowering high-growth firms to disrupt markets, fostering innovation through training and prototypes that democratize AI access without heavy in-house development. This positions Forty Seven as a bridge between hype and execution in a landscape shifting toward agentic AI and human-AI harmony.[1][2]
Forty Seven is primed to scale as AI demand explodes, likely expanding custom agent builds and training amid Web3-AI convergence and enterprise upskilling needs. Trends like multimodal AI and regulatory pushes will shape its path, amplifying its role in turning adopters into leaders.
With founders' pedigrees driving purposeful innovation, expect deeper partnerships yielding case-study wins—echoing its core mission to evolve businesses from players to disruptors in an AI-first world.[1][2]
Forty Seven has raised $160.2M in total across 3 funding rounds.
Forty Seven's investors include Lee Greenberger, Wellington Management, Bluebird Ventures, David Chen, Dennis Henner, Google Ventures, Lightspeed Venture Partners, Sutter Hill Ventures, Christopher Schaepe, Jeff Bird.
Forty Seven has raised $160.2M across 3 funding rounds. Most recently, it raised $10.2M Other Equity in August 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 6, 2019 | $10.2M Venture Round | LEE Greenberger | — | Announced |
| Oct 1, 2017 | $75M Series B | Wellington Management | Bluebird Ventures, David Chen, Dennis Henner, GV, Lightspeed Venture Partners, Sutter Hill Ventures | Announced |
| Feb 1, 2016 | $75M Series A | Christopher Schaepe, Jeff Bird | Bluebird Ventures, David Chen, Dennis Henner, GV | Announced |